Humanized Monoclonal Antibody 3F8 (Hu3F8)
Showing 1 - 25 of >10,000
Recurrent Osteosarcoma Trial in Los Angeles, New York, Houston (humanized anti-GD2 antibody, GM-CSF)
Recruiting
- Recurrent Osteosarcoma
- humanized anti-GD2 antibody
- GM-CSF
-
Los Angeles, California
- +2 more
Dec 22, 2022
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Negative Breast Carcinoma Trial in Columbus (procedure, drug, biological)
Not yet recruiting
- Anatomic Stage IV Breast Cancer AJCC v8
- HER2-Negative Breast Carcinoma
- Biospecimen Collection
- +5 more
-
Columbus, OhioOhio State University Comprehensive Cancer Center
Aug 30, 2023
Neuroblastoma Trial in New York (Humanized 3F8 Monoclonal Antibody (Hu3F8))
Active, not recruiting
- Neuroblastoma
- Humanized 3F8 Monoclonal Antibody (Hu3F8)
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Aug 24, 2021
Neuroblastoma Trial in New York (3F8 Monoclonal Antibody Combined with Interleukin-2)
Completed
- Neuroblastoma
- 3F8 Monoclonal Antibody Combined with Interleukin-2
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 26, 2021
Neuroblastoma, Osteosarcoma, Other Solid Tumor Cancers Trial in New York (Humanized 3F8 Bispecific Antibody, Blood draw)
Terminated
- Neuroblastoma
- +2 more
- Humanized 3F8 Bispecific Antibody
- Blood draw
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 11, 2022
Melanoma, Neuroblastoma, Sarcoma Trial in New York (124I-Humanized 3F8)
Active, not recruiting
- Melanoma
- +2 more
- 124I-Humanized 3F8
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Dec 1, 2022
Neuroblastoma Trial in New York (Hu3F8 With GM-CSF)
Active, not recruiting
- Neuroblastoma
- Hu3F8 With GM-CSF
-
New York, New YorkMemorial Sloan Kettering Cancer Center
May 2, 2022
Neuroblastoma Trial in Guangzhou (Naxitamab monotherapy, GM-CSF, Irinotecan)
Recruiting
- Neuroblastoma
- Naxitamab monotherapy
- +6 more
-
Guangzhou, Guangdong, ChinaSun Yat-sen University Cancer Center
Aug 31, 2023
Neuroblastoma, High-Risk Trial in New York (cyclophosphamide, NK cells, hu3F8)
Active, not recruiting
- Neuroblastoma
- High-Risk
- cyclophosphamide
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Feb 14, 2022
Neuroblastoma Trial in New York (Hu3F8, GM-CSF, Isotretinoin)
Active, not recruiting
- Neuroblastoma
- Hu3F8
- +2 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Jul 1, 2022
Neuroblastoma Trial in New York (anti-GD2 murine IgG3 mAb 3F8)
Completed
- Neuroblastoma
- anti-GD2 murine IgG3 monoclonal antibody 3F8
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Apr 21, 2022
Neuroblastoma Trial in New York (beta-glucan, mAb 3F8, immunohistochemistry staining method)
Completed
- Neuroblastoma
- beta-glucan
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Mar 4, 2022
Ovarian Cancer Trial in New York (90Y-hu3S193, 111In-hu3S193)
Completed
- Ovarian Cancer
- 90Y-hu3S193
- 111In-hu3S193
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Oct 3, 2022
Ovarian Cancer Trial in New York (Monoclonal antibody hu3S193)
Terminated
- Ovarian Cancer
- Monoclonal antibody hu3S193
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Oct 3, 2022
Colorectal Cancer Trial in New York (mAb hu3S193)
Terminated
- Colorectal Cancer
- monoclonal antibody hu3S193
-
New York, New YorkMemorial Sloan-Kettering Cancer Center
Oct 3, 2022
Brain and CNS Tumors, Intraocular Melanoma, Lung Cancer Trial in New York (genetic, other, radiation)
Active, not recruiting
- Brain and Central Nervous System Tumors
- +9 more
- DNA analysis
- +4 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 28, 2021
Metastatic Lung Non-Small Cell Carcinoma, Refractory Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer American Joint
Recruiting
- Metastatic Lung Non-Small Cell Carcinoma
- +4 more
- Necitumumab
- +4 more
-
Los Angeles, CaliforniaUCLA / Jonsson Comprehensive Cancer Center
Jan 5, 2023
Nodular Lymphocyte Predominant Hodgkin Lymphoma, Recurrent Nodular Lymphocyte Predominant Hodgkin Lymphoma, Refractory Nodular
Not yet recruiting
- Nodular Lymphocyte Predominant Hodgkin Lymphoma
- +2 more
- Biopsy
- +9 more
- (no location specified)
Jun 1, 2023
Neuroblastoma Trial in Worldwide (GM-CSF + Naxitamab)
Recruiting
- Neuroblastoma
- GM-CSF + Naxitamab
-
Gainesville, Florida
- +22 more
Aug 29, 2022
Prostate Adenocarcinoma, Stage I Prostate Cancer AJCC v8, Stage IIA Prostate Cancer AJCC v8 Trial in Chicago (procedure,
Not yet recruiting
- Prostate Adenocarcinoma
- +3 more
- Biopsy of Prostate
- +6 more
-
Chicago, IllinoisNorthwestern University
May 9, 2023
Neuroblastoma (NB) Trial in New York (Irinotecan, temozolomide, Hu3F8)
Active, not recruiting
- Neuroblastoma (NB)
- Irinotecan
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Oct 19, 2021
Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8 Trial
Recruiting
- Anatomic Stage I Breast Cancer AJCC v8
- +19 more
- pUMVC3-IGFBP2-HER2-IGF1R Plasmid DNA Vaccine
- +3 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Aug 1, 2022
Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8, Clinical Stage IV Merkel Cell Carcinoma AJCC v8, Merkel Cell
Not yet recruiting
- Unresectable Clinical Stage III Merkel Cell Carcinoma AJCC v8
- +2 more
- Biopsy
- +6 more
-
Seattle, WashingtonFred Hutch/University of Washington Cancer Consortium
Sep 28, 2023
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIB Breast Cancer AJCC v8
Recruiting
- Anatomic Stage III Breast Cancer AJCC v8
- +12 more
- Carboplatin
- +5 more
-
Houston, TexasM D Anderson Cancer Center
Jun 16, 2022
Classic Hodgkin Lymphoma Trial (procedure, biological, drug, other, radiation)
Not yet recruiting
- Classic Hodgkin Lymphoma
- Biospecimen Collection
- +19 more
- (no location specified)
Jan 6, 2023